Media.Player

Novel Gamma-Secretase Modulators for the Treatment of Alzheimer's Disease and Related Neurodegenerative Disorders

Detailed Technology Description

Researchers at UC San Diego have developed methods for synthesizing and testing a number of novel gamma-secretase modulators with dramatically improved aqueous solubilities. The enhanced aqueous solubilities of these gamma-secretase modulators are expected to exhibit improved pharmacokinetic and pharmacodynamic properties compared to the 2-aminothiazole GSM compounds previously described in U.S. patent 7,244,739. The present invention is a new class of soluble GSMs that promises to be far more amenable to preclinical and clinical development protocols as a result of their enhanced aqueous solubilities. SGSM technology covered by this invention may prove useful for treating diseases associated with altered levels of certain Aβ peptide alloforms (i.e., Aβ42 and Aβ40), such as Alzheimer’s disease, Down’s syndrome, hereditary cerebral hemorrhage with amyloidosis-Dutch Type, cerebral amyloid angiopathy, and mild cognitive impairment, as well as a number of other neurodegenerative proteinopathies (e.g. Creutzfeldt-Jakob disease, frontotemporal dementias, amyotropic lateral sclerosis, Huntington’s disease, Parkinson’s disease).

Supplementary Information

Inventor: WAGNER, Steven, L. | CHENG, Soan | MOBLEY, William, C. | TANZI, Rudolph, E.
Priority Number: WO2011163636A3
IPC Current: C07D041714 | A61K00314427 | A61K00314439 | A61P002500 | C07D040104
Assignee Applicant: The Regents of the University of California
Title: COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | COMPOSÉS ET LEURS UTILISATIONS DANS LA MODULATION DES NIVEAUX DE DIFFÉRENTES ALLOFORMES DU PEPTIDE AMYLOÏDE BÊTA
Usefulness: COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | COMPOSÉS ET LEURS UTILISATIONS DANS LA MODULATION DES NIVEAUX DE DIFFÉRENTES ALLOFORMES DU PEPTIDE AMYLOÏDE BÊTA
Summary: For treating a disease or neurological disorder associated with elevated levels of specific fibrillogenic (Aβ ) peptides, the disease is selected from Alzheimer's disease, hemorrhagic stroke associated with cerebrovascular amyloidosis (HCHWA), or cerebral amyloid angiopathy (CAA), idiopathic dilated cardiomyopathy, Down Syndrome (DS), Parkinson's disease (PD), Lewy body dementia (LBD), Prion diseases, inclusion body myositis (IBM), or Huntington's disease (HD) (all claimed), also for treating mild cognitive impairment, or amyotrophic lateral sclerosis.
Novelty: New tetra-(hetero)aryl compounds useful for treatment of e.g. Alzheimer's disease, hemorrhagic stroke associated with cerebrovascular amyloidosis, or Parkinson's disease

Industry

Chemical/Material

Sub Category

Chemical/Material Application

Application No.

9403815

Others

Intellectual Property Info

See PCT/US2011/041905 (WO 2011/163636).

Related Materials

Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, Nguyen P, Comer D, Mao L, Yu C, Pleynet D, Digregorio PJ, Velicelebi G, Stauderman KA, Comer WT, Mobley WC, Li YM, Sisodia SS, Tanzi RE, Wagner SL. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. Neuron. 2010 Sep 9;67(5):769-80. doi: 10.1016/j.neuron.2010.08.018.
Wagner SL, Tanzi RE, Mobley WC, Galasko D. Potential use of gamma-secretase modulators in the treatment of Alzheimer disease. Arch Neurol. 2012 Oct;69(10):1255-8.

Tech ID/UC Case

21149/2010-246-0

Related Cases

2010-246-0, 2013-201-0

*Abstract

Thirty million people worldwide are currently living with Alzheimer’s disease (AD) and unless the disease can be effectively prevented, this number will balloon in aging populations. For example, in the U.S. the number of people age 65 and older is expected to increase from 39 million in 2008 to 72 million in 2030, with the number of people with AD doubling every 5-year interval over the age of 65.

A key pathological indication of AD is an overabundance of neuritic plaques in regions of the brain participating in memory and cognition. Research has confirmed that Aβ42 forms the "seed" of these amyloid plaques, which gradually accumulate in the brain and induce cell death in the underlying brain tissue. It is widely accepted that all Aβ peptides are derived from proteolytic processing of an amyloid precursor protein (APP). Several drug discovery strategies including inhibition of gamma-secretase have been used to inhibit Aβ42 production from amyloid precursor protein. However, the involvement of gamma-secretase inhibitors in the proteolysis of several other substrates (e.g. Notch receptors) can lead to adverse effects (e.g. triggering goblet cell hyperplasia in the gastrointestinal tract).

Alternatively, gamma-secretase modulators (GSMs), such as those described in U.S. patent 7,244,739, lower the production of toxic, longer forms of Aβ, such as Aβ42, and promote the formation of smaller, less toxic Aβ peptides (Aβ37 and Aβ38) at nanomolar potencies. The design of gamma-secretase modulators for the treatment of AD is rapidly expanding, yet most of the gamma-secretase modulators cited in the literature are non-steroidal anti-inflammatory drugs (NSAIDs) and suffer from poor potency and minimal brain penetration.

*IP Issue Date

Aug 2, 2016

*Principal Investigator

Name: Soan Cheng

Department:

Name: William C. Mobley

Department:

Name: Rudolph Tanzi

Department:

Name: Steven Wagner

Department:

Country/Region

USA